We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Molecular Assay Diagnoses Eight Gastrointestinal Parasites

By LabMedica International staff writers
Posted on 19 Aug 2013
A novel, rapid, high-throughput quantitative multiparallel real-time polymerase chain reaction (qPCR) platform has been developed for the diagnosis of gastrointestinal parasites. More...


The diagnosis of gastrointestinal parasites has traditionally relied on stool microscopy, which has low diagnostic sensitivity and specificity as the ability of the microscopist to detect parasites is directly related to the number of organisms in the stool.

Helminthologists at the US National Institutes of Health (Bethesda, MD, USA) working with others, collected fecal samples from 400 asymptomatic children, 13 months of age, living in, Ecuador. The children were part of a larger ongoing birth cohort study in which direct microscopy and the Kato-Katz method were performed at the time of stool collection. A second group of 125 asymptomatic children eight to 14 years of age also had fecal samples collected as part of a separate study of anthelmintic treatment.

Species-specific primers/probes were used for eight common gastrointestinal parasite pathogens: Ascaris lumbricoides, Necator americanus, Ancylostoma duodenale, Giardia lamblia, Cryptosporidium spp., Entamoeba histolytica, Trichuris trichiura, and Strongyloides stercoralis. All qPCRs were conducted in 96-well MicroAmp optical plates (Applied Biosystems; Foster City, CA, USA) and the samples were run on Applied Biosystem’s ABI 7900HT Fast Real-Time PCR System and compared with a standard direct wet mount slide for stool microscopy.

The qPCR showed higher detection rates for all parasites compared with direct microscopy. For example, the molecular assay identified Ascaris in 28 of 400 (7.0%) of positive samples whereas direct smears identified 22 of 400 (5.5%) positive samples. The difference between qPCR and microscopy was seen even more dramatically for G. lamblia with 103 additional positive samples for this parasite with 126 of 400 (31.5%) with qPCR versus 23 of 400 (5.8%) by microscopy. The qPCR was able to distinguish between patients without parasites and those with polyparasitism more accurately and with greater detection rates than direct smear microscopy.

The authors concluded that the high throughput system that has been field tested in a resource-limited area provides a sensitive and specific approach to gastrointestinal parasitism and polyparasitism, with broad implications for community based therapies and methods for assessing efficacy of treatment. The study was published in the August 2013 edition of the American Journal of Tropical Medicine and Hygiene.

Related Links:

US National Institutes of Health
Applied Biosystems



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.